EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Engineering Metal‐Organic‐Framework‐Based STING Nanoagonists for PROTAC‐Enhanced Cancer Chemo‐Metalloimmunotherapy

Zhenzhen Chen, Zhe Feng, Siyuan Wang, Jingjing Zhang iD

Advanced Science · 2026-01 · 13 (2)

DOI: 10.1002/advs.202515006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 13.10.2025. Verfasst von Zhenzhen Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Analytical Chemistry for Life Science, School of Chemistry and Chemical Engineering, Chemistry and Biomedicine Innovation Cen…. Hauptthemen laut MEDLINE: Immunotherapy, Metal-Organic Frameworks, Membrane Proteins, Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundamental Research Funds for the Central Universities, State Key Laboratory of Analytical Chemistry for Life Science, Natural Science Foundation of Jiangsu Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chemo‐metalloimmunotherapy is emerging as a promising strategy for cancer treatment by integrating chemotherapy‐induced immunogenicity with metal ion‐mediated immune activation. However, its efficacy is hampered by chemoresistance and immune escape driven by PD‐L1 upregulation. Here, a multifunctional manganese‐based metal‐organic framework nanoplatform (Mn‐CDDP‐dBET6@CM) is reported that integrates metalloimmunotherapy, chemotherapy, and Proteolysis‐targeting chimera (PROTAC) ‐mediated epigenetic modulation for enhanced cancer treatment. This system co‐delivers Mn 2+ to activate the stimulator of interferon genes (STING) pathway, cisplatin (CDDP) to induce nucleus DNA damage, and the bromodomain‐containing protein 4 (BRD4) ‐targeting PROTAC dBET6 to promote mitochondrial DNA release and suppress PD‐L1‐mediated immune evasion. Coated with tumor cell membranes for homologous targeting and immune evasion, Mn‐CDDP‐dBET6@CM effectively induces cellular senescence, robust innate and adaptive immune activation, and tumor microenvironment remodeling. In vitro and in vivo studies demonstrate potent tumor growth inhibition, enhance dendritic cell maturation, and increase cytotoxic T cell infiltration. This nanoplatform offers a promising strategy to overcome chemoresistance and immunosuppression, providing a versatile approach for next‐generation chemo‐metalloimmunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyMetal-Organic FrameworksMembrane ProteinsNeoplasmsAnimalsMiceHumansCisplatinCell Line, TumorAntineoplastic AgentsTumor MicroenvironmentSTING Protein

Stichwörter der Autor:innen

PROTACSTING activationcancer therapychemotherapymetalloimmunotherapy

Substanzen

Metal-Organic FrameworksCisplatinMembrane ProteinsAntineoplastic AgentsSTING1 protein, humanSTING Protein

Autor:innen und Institutionen

  • State Key Laboratory of Analytical Chemistry for Life Science, School of Chemistry and Chemical Engineering, Chemistry and Biomedicine Innovation Center (ChemBIC), Nanjing University, Nanjing, 210023, China.

ORCID-Profile: Jingjing Zhang

Förderung

  • Fundamental Research Funds for the Central Universities
  • State Key Laboratory of Analytical Chemistry for Life Science
  • Natural Science Foundation of Jiangsu Province
  • National Natural Science Foundation of China

Zitieren

APA

Chen, Z., Feng, Z., Wang, S., & Zhang, J. (2026). Engineering Metal‐Organic‐Framework‐Based STING Nanoagonists for PROTAC‐Enhanced Cancer Chemo‐Metalloimmunotherapy. Advanced Science, 13(2). https://doi.org/10.1002/advs.202515006

Vancouver

Chen Z, Feng Z, Wang S, Zhang J. Engineering Metal‐Organic‐Framework‐Based STING Nanoagonists for PROTAC‐Enhanced Cancer Chemo‐Metalloimmunotherapy. Advanced Science. 2026;13(2). doi:10.1002/advs.202515006

BibTeX
@article{Chen2026,
  author = {Chen, Zhenzhen and Feng, Zhe and Wang, Siyuan and Zhang, Jingjing},
  title = {Engineering Metal‐Organic‐Framework‐Based STING Nanoagonists for PROTAC‐Enhanced Cancer Chemo‐Metalloimmunotherapy},
  journal = {Advanced Science},
  year = {2026},
  volume = {13},
  number = {2},
  doi = {10.1002/advs.202515006}
}
Kostenlos starten →